 | Up a level |
Finckh, A; Ciurea, A; Burlhart, L; Möller, B; Walker, UA; Courvoisier, D; Kyburz, D; Dudler, J; Gabay, C (2009). Which Subgroup of Rheumatoid Arthritis Patients Benefits Most From Swichting to Rituximab Versus Alternative Anti-TNF Agenst After Previous Failure To Anit-TNF Agent? Annals of the rheumatic diseases, 69(2), pp. 387-393. London: BMJ Publishing Group 10.1136/ard.2008.105064
Finckh, A; Ciurea, A; Brulhart, L; Kyburz, D; Möller, B; Dehler, S; Reveaz, S; Dudler, J; Gabay, C (2007). B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis & rheumatism, -56(5), pp. 1417-23. Hoboken, N.J.: Wiley-Blackwell 10.1002/art.22520
